Industry Roundup
This article was originally published in The Tan Sheet
Executive Summary
FDA warns eye supplement marketer; Kentucky age-restricts OTC DXM sales; FDA, EPA data-sharing pact; Colorado, Maine pass microbead laws; and more news in brief.
You may also be interested in...
FDA Guidance Stirs In Caffeine Restrictions For Supplements
"An inherent feature of the conditions of use for such products is that the consumer must separate out a very small, precise serving from a potentially lethal amount of product – a task that poses a significant or unreasonable risk of illness or injury," says FDA's Office of Dietary Supplement Programs. Only products containing pure caffeine that packaged in the ingredient in premeasured doses and bulk caffeine that is sufficiently diluted will be considered compliant.
Trade Groups Expand Caffeine Labeling To Stave Off Tighter Regs
The Council for Responsible Nutrition and the American Herbal Products Association amend guidelines and requirements for labeling and marketing caffeine-containing products, going beyond the law in response to congressional and public health complaints about the ingredient’s safety.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.